Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600276 Jiangsu Hengrui Pharmaceuticals Co.,Ltd.

Closed 12-18 15:00:00

60.00

-0.30

-0.50%

High60.57	Low59.95	Vol17.93M
Open60.05	D1 Closing60.30	Amplitude1.03%
Mkt Cap398.22B	Tradable Cap382.74B	Total Shares6.64B
T/O1.08B	T/O Rate0.28%	Tradable Shares6.38B
P/B6.69	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.","latestPrice":60,"timestamp":1766041200000,"preClose":60.3,"halted":0,"volume":17930929,"delay":0,"changeRate":-0.005,"floatShares":6379000000,"shares":6637000000,"eps":1.1252,"marketStatus":"Closed","change":-0.3,"latestTime":"12-18 15:00:00","open":60.05,"high":60.57,"low":59.95,"amount":1079000000,"amplitude":0.0103,"askPrice":60.01,"askSize":35,"bidPrice":60,"bidSize":563,"shortable":0,"etf":0,"ttmEps":1.1252,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766107800000},"marketStatusCode":5,"adr":0,"adjPreClose":60.3,"symbolType":"stock","openAndCloseTimeList":[[1766021400000,1766028600000],[1766034000000,1766041200000]],"highLimit":66.33,"lowLimit":54.27,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":6.69,"roa":"--","peRate":53.323854,"roe":"11.09%","epsLYR":1,"committee":0.583082,"marketValue":398232000000,"turnoverRate":0.0028,"status":1,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"HENGRUI PHARMA","latestPrice":70.7,"timestamp":1766045294005,"preClose":71.3,"halted":0,"volume":1563200,"delay":0,"premium":"+6.51"},"floatMarketCap":382740000000},"requestUrl":"/m/hq/s/600276/wiki","defaultTab":"wiki","newsList":[{"id":"2591644163","title":"BRIEF-JPMorgan& Co's Long Position In H-Shares Of Jiangsu Hengrui Pharmaceuticals Increases To 8.29%, HKEX Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2591644163","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591644163?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:03","pubTimestamp":1765807407,"startTime":"0","endTime":"0","summary":"BRIEF-JPMorgan& Co's Long Position In H-Shares Of Jiangsu Hengrui Pharmaceuticals Increases To 8.29%, HKEX SaysDec 15  - HKEX:JPmorgan Chase & Co's Long Position In H-Shares Of Jiangsu Hengrui Pharmaceuticals Increases To 8.29% On Dec 9 From 6.79%Further company coverage: 1276.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL019:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064130708.USD","LU1997245177.USD","LU0405327148.USD","LU1255011170.USD","BK0028","LU1781817850.SGD","LU2289578879.USD","LU2097828714.EUR","LU1997244956.HKD","LU0405327494.USD","LU2097828474.EUR","BK0239","LU2097828805.USD","BK0183","BK0188","600276","LU1580142542.USD","LU2328871848.SGD","LU2495084118.USD","BK0012","LU1328615791.USD","BK0060","LU2580892789.USD","LU2097828557.USD","LU1146622755.USD","LU1655091616.SGD","LU2148510915.USD","LU2488822045.USD","LU1997245094.SGD","LU2580892862.HKD","LU1969619763.USD","BK0196","LU1064131003.USD","LU2097828631.EUR","LU1820825898.SGD"],"gpt_icon":0},{"id":"1104132943","title":"JPMorgan Increases Stake in Hengrui Pharma (01276) by 3.88 Million Shares at HK$72.60 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1104132943","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104132943?lang=en_us&edition=fundamental","pubTime":"2025-12-15 19:20","pubTimestamp":1765797644,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on December 9, JPMorgan increased its stake in Hengrui Pharma (01276) by 3.88 million shares at HK$72.60 per share, totaling...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","LU1084165304.USD","LU0070302665.USD","LU0820561909.HKD","LU2417539215.USD","IE00BJTD4V19.USD","LU0238689110.USD","LU0203345920.USD","LU0964807845.USD","LU0976567544.SGD","LU0359201612.USD","IE00BWXC8680.SGD","LU0265550946.USD","LU0345770993.USD","IE00BN8TJ469.HKD","LU0787776722.HKD","LU1548497426.USD","LU1781817850.SGD","LU0170899867.USD","JPM","LU2552382058.USD","LU0345769128.USD","BK4566","IE00BLSP4239.USD","LU0942090050.USD","BK4533","LU0267386448.USD","LU1670628061.USD","LU1720051017.SGD","LU0820562030.AUD","LU2381873111.SGD","LU2543165471.USD","LU0234572021.USD","LU1261432733.SGD","BK0183","LU2289578879.USD","LU1328615791.USD","LU0359202008.SGD","LU2746668974.SGD","LU1267930490.SGD","BK0060","LU2237443895.HKD","LU2242649171.HKD","IE00BHPRN162.USD","LU1280957306.USD","LU2023250330.USD","LU1366192091.USD","LU0868494617.USD","LU1116320737.USD","LU0345769631.USD","IE00B1BXHZ80.USD","IE00BKDWB100.SGD","IE00BJLML261.HKD","LU0149725797.USD","LU0868494708.USD","LU0417517546.SGD","LU2357305700.SGD","LU1244550221.USD","LU0211326839.USD","LU2097828805.USD","LU1974910355.USD","LU2328871848.SGD","LU2756315318.SGD","LU2148510915.USD","LU1064130708.USD","LU1551013342.USD","IE00BLSP4452.SGD","LU0211326755.USD","BK4550","LU2097828631.EUR","LU1894683348.USD","LU2264538146.SGD","LU2430703251.USD","LU1146622755.USD","LU1162221912.USD","LU0251132253.USD","LU0323591593.USD","LU2211815571.USD","LU0048584097.USD","LU1820825898.SGD","LU0211327993.USD","LU1580142542.USD","LU1670627923.USD","LU0208291251.USD","LU1655091616.SGD","LU2505996681.GBP","LU0882574139.USD","LU0265550359.USD","LU0405327148.USD","LU1119994496.HKD","LU0211328371.USD","LU2023250843.SGD","BK1191","SG9999002232.USD","BK4207","LU1032466523.USD","BK4581","LU1064131003.USD","LU2054465674.USD","LU0215105999.USD","LU2097828714.EUR","LU0971096721.USD","LU1244550577.SGD","LU1244550494.USD","600276","LU1969619763.USD","IE0034235188.USD","BK0239","LU0106831901.USD","LU1496350502.SGD","LU2430703178.SGD","LU2097828557.USD","LU1917777945.USD","LU0320765646.SGD","LU2488822045.USD","LU0310799852.SGD","LU0640476718.USD","LU1116320901.HKD","LU0496365809.HKD","LU2746668461.USD","LU1668664300.SGD","IE000M9KFDE8.USD","IE00BDRTCR15.USD","BK0012","LU1023057109.AUD","LU2430703095.HKD","LU2237443382.USD","LU2456880835.USD","LU1629891620.HKD","BK0028","IE00BJTD4N35.SGD","01276","LU1997245177.USD","LU2097828474.EUR","LU0256863811.USD","LU2213496289.HKD","BK4588","LU1988902786.USD","LU2505996509.AUD","LU1914381329.SGD","LU0683600562.USD","BK4534","LU2237443465.HKD","LU2237443549.SGD","IE00B1XK9C88.USD","BK4516","IE00BDCRKT87.USD","IE00BFXG1179.USD","LU2756315664.SGD","LU0405327494.USD","LU2236285917.USD","LU1997244956.HKD","IE0034235295.USD","LU2462157665.USD","BK4504","LU1064131342.USD","IE00BKVL7J92.USD","LU1145028129.USD","LU1255011170.USD","SG9999002224.SGD","LU1997245094.SGD","IE00B775SV38.USD","LU2580892862.HKD","LU0211331839.USD","LU0320765489.SGD","LU2495084118.USD","LU0943347566.SGD","LU2237443622.USD","LU2592432038.USD","IE00BYXW3230.USD","LU2580892789.USD","LU1894683264.USD","LU2237443978.SGD","LU2552382132.HKD","IE00BBT3K403.USD","LU1363072403.SGD","IE0034235303.USD","LU2023250504.SGD","BK0188","LU1496350171.SGD","IE00B3S45H60.SGD","LU0689472784.USD","LU0345770308.USD","LU0106261372.USD","LU0006306889.USD","LU2106854487.HKD","LU0359201885.HKD","LU1551013425.SGD","BK4585","LU0203347892.USD","LU0820561818.USD","LU1720051108.HKD","BK0196","LU2552382215.SGD"],"gpt_icon":0},{"id":"2591614975","title":"JPMorgan Chase & Co's Long Position in H-Shares of Jiangsu Hengrui Pharmaceuticals  Increases to 8.29% on Dec 9 From 6.79% - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2591614975","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591614975?lang=en_us&edition=fundamental","pubTime":"2025-12-15 17:21","pubTimestamp":1765790460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nFWN3XL019:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0196","LU1064130708.USD","LU1146622755.USD","LU2097828714.EUR","BK0239","600276","LU1580142542.USD","LU2097828631.EUR","LU2097828805.USD","LU0405327148.USD","LU2097828557.USD","LU1781817850.SGD","LU1997245094.SGD","LU2289578879.USD","LU0405327494.USD","BK0012","LU2580892789.USD","LU2097828474.EUR","LU1655091616.SGD","LU2328871848.SGD","LU1820825898.SGD","BK0183","LU1328615791.USD","LU1255011170.USD","LU2488822045.USD","BK0028","LU2580892862.HKD","LU1969619763.USD","LU2148510915.USD","BK0188","LU1997245177.USD","LU1997244956.HKD","LU2495084118.USD","BK0060","LU1064131003.USD"],"gpt_icon":0},{"id":"1198911588","title":"HENGRUI PHARMA's Ovarian Cancer Drug Fuzuloparib (FZOCUS-1 Study) Published in Top Oncology Journal \"CA\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1198911588","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198911588?lang=en_us&edition=fundamental","pubTime":"2025-12-15 14:00","pubTimestamp":1765778439,"startTime":"0","endTime":"0","summary":"The FZOCUS-1 study, led by Chinese researchers, has been published in the globally renowned oncology journal *CA: A Cancer Journal for Clinicians* (impact factor: 232.4). This marks the first time...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997245094.SGD","LU2289578879.USD","BK0196","LU2580892862.HKD","LU0405327148.USD","LU1064130708.USD","LU2543165471.USD","BK0028","LU1580142542.USD","LU1820825898.SGD","CA","LU1023057109.AUD","LU2495084118.USD","LU1146622755.USD","LU2097828805.USD","LU1328615791.USD","LU1655091616.SGD","LU1997245177.USD","LU1064131003.USD","LU2097828631.EUR","BK0060","LU1969619763.USD","LU0359202008.SGD","LU0405327494.USD","LU0359201885.HKD","BK0183","BK0012","600276","LU0359201612.USD","BK0188","LU1781817850.SGD","01276","LU2488822045.USD","LU2097828714.EUR","LU2328871848.SGD","BK0239","LU1997244956.HKD","LU2097828474.EUR","LU1255011170.USD","BK1191","LU2097828557.USD","LU2148510915.USD","LU2580892789.USD"],"gpt_icon":0},{"id":"2591692707","title":"Hengrui Medicine's Unit Gets Nod to Trial Heart Failure Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2591692707","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591692707?lang=en_us&edition=fundamental","pubTime":"2025-12-15 13:00","pubTimestamp":1765774842,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine's  unit, Shandong Shengdi Pharmaceutical, received approval from China's National Medical Products Administration to conduct clinical trials on HRS-1780 tablets, according to a Shanghai bourse disclosure on Saturday.The pharmaceutical company's Shanghai shares fell 2% and Hong Kong shares slipped less than 1% during Monday's midday trade.The drug will be tested as a treatment for adult patients with heart failure with a left ventricular ejection fraction of more than 40%.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1580142542.USD","LU1328615791.USD","BK0239","LU1655091616.SGD","LU2097828714.EUR","LU1146622755.USD","LU1997244956.HKD","LU2097828631.EUR","LU1997245094.SGD","LU0405327494.USD","LU1781817850.SGD","LU1023057109.AUD","LU1064131003.USD","BK0196","LU2148510915.USD","LU2580892862.HKD","LU1064130708.USD","LU2289578879.USD","LU2097828474.EUR","LU1997245177.USD","LU2097828557.USD","LU2495084118.USD","BK0188","LU2488822045.USD","BK0060","LU0359201885.HKD","LU0405327148.USD","LU2580892789.USD","BK1191","BK0183","01276","LU2097828805.USD","LU2328871848.SGD","BK0028","600276","LU1969619763.USD","LU2543165471.USD","BK0012","LU1255011170.USD","LU1820825898.SGD","LU0359202008.SGD","LU0359201612.USD"],"gpt_icon":0},{"id":"1171121813","title":"Guosen Securities: FXI Inhibitors Poised as Next-Gen Anticoagulants, Recommends Focus on Hengrui Pharma (600276.SH)","url":"https://stock-news.laohu8.com/highlight/detail?id=1171121813","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171121813?lang=en_us&edition=fundamental","pubTime":"2025-12-15 10:58","pubTimestamp":1765767506,"startTime":"0","endTime":"0","summary":"FXI/FXIa inhibitors are emerging as potential upgrades to existing anticoagulants, offering improved safety profiles with reduced bleeding risks, according to a research report by Guosen Securities....","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","LU2289578879.USD","LU1064130708.USD","LU2097828557.USD","LU2097828805.USD","LU2097828631.EUR","BK0012","LU0405327494.USD","LU2488822045.USD","LU2148510915.USD","LU0405327148.USD","LU1997245094.SGD","600276","01276","LU1580142542.USD","LU1781817850.SGD","LU1997245177.USD","LU2543165471.USD","BK0028","BK0196","LU1328615791.USD","BK0183","LU1969619763.USD","LU2097828714.EUR","002736","LU2580892789.USD","LU1255011170.USD","BK0239","LU1146622755.USD","LU2097828474.EUR","LU1064131003.USD","BK0276","BK0188","LU1820825898.SGD","LU1655091616.SGD","LU1997244956.HKD","LU2328871848.SGD","LU2580892862.HKD","LU2495084118.USD","LU0359201612.USD","LU1023057109.AUD","LU0359201885.HKD","BK0060","LU0359202008.SGD"],"gpt_icon":0},{"id":"2590570517","title":"BRIEF-Morgan Stanley's Long Position In H-Shares Of Jiangsu Hengrui Pharmaceuticals Decreases To 2.76% On Dec 8 - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2590570517","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590570517?lang=en_us&edition=fundamental","pubTime":"2025-12-12 18:29","pubTimestamp":1765535395,"startTime":"0","endTime":"0","summary":"BRIEF-Morgan Stanley's Long Position In H-Shares Of Jiangsu Hengrui Pharmaceuticals Decreases To 2.76% On Dec 8 - HKEXDec 12  - MORGAN STANLEY'S LONG POSITION IN H-SHARES OF JIANGSU HENGRUI PHARMACEUTICALS 1276.HK DECREASES TO 2.76% ON DEC 8 FROM 6.60% - HKEXFurther company coverage: 1276.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XH17Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997245094.SGD","LU2543165471.USD","LU1781817850.SGD","LU1328615791.USD","LU2097828557.USD","LU2097828474.EUR","LU1064130708.USD","BK0239","LU1023057109.AUD","LU0359201612.USD","LU2289578879.USD","BK0028","BK0012","LU0359201885.HKD","BK0060","LU1820825898.SGD","LU2097828805.USD","BK0188","LU2488822045.USD","LU2580892789.USD","LU0359202008.SGD","LU1146622755.USD","LU0405327494.USD","LU1580142542.USD","LU2580892862.HKD","LU1655091616.SGD","BK1191","LU1255011170.USD","LU1969619763.USD","BK0183","LU2495084118.USD","LU1997244956.HKD","01276","LU2097828714.EUR","600276","LU2097828631.EUR","LU1997245177.USD","BK0196","LU2328871848.SGD","LU1064131003.USD","LU2148510915.USD","LU0405327148.USD"],"gpt_icon":0},{"id":"2590590792","title":"3SBio Sells Shares, Divests Subsidiary To Boost Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2590590792","media":"Benzinga_recent_news","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590590792?lang=en_us&edition=fundamental","pubTime":"2025-12-11 19:23","pubTimestamp":1765452180,"startTime":"0","endTime":"0","summary":"After grabbing the spotlight this year with a big licensing deal, the Chinese drug developer is now raising extra funds for R&D and shedding a non-core subsidiary. After its market value rose above HK$70 billion, the companyannouncedon Dec. 2 it was placing 105 million shares, or about 4.14% of its enlarged share capital, to raise additional money to invest in the highly competitive field of innovative drugs. The shares were priced at HK$29.62, a 6.5% discount to the previous closing price, with net proceeds after fees estimated at HK$3.09 billion.This plan aligns with 3SBio's strategic shift in recent years toward prioritizing innovation. From 2022 to 2024, the company's R&D expenditure rose from 690 million yuan to 1.33 billion yuan, while the research bill in the first half of 2025 was 15% higher than in the same period a year earlier. The company has 30 experimental drugs in its pipeline, including 27 innovative treatments spanning oncology and autoimmune diseases. Among them, four","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/11/image.png?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/11/image.png?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/Opinion/25/12/49328004/3sbio-sells-shares-divests-subsidiary-to-boost-capital","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/Opinion/25/12/49328004/3sbio-sells-shares-divests-subsidiary-to-boost-capital","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK0060","LU2488822045.USD","LU2289578879.USD","LU1781817850.SGD","BK0012","LU1820825898.SGD","BK0196","LU2580892789.USD","BK0239","LU2328871848.SGD","BK0188","LU2097828631.EUR","LU1580142542.USD","LU1997245094.SGD","BK0028","LU1146622755.USD","LU1655091616.SGD","LU2097828557.USD","LU1328615791.USD","LU1997244956.HKD","LU1997245177.USD","BK0183","600276","LU2148510915.USD","LU1255011170.USD","LU1064130708.USD","LU2097828805.USD","LU1969619763.USD","LU2097828474.EUR","LU0405327494.USD","LU2495084118.USD","LU2580892862.HKD","LU0405327148.USD","LU2097828714.EUR","LU1064131003.USD"],"gpt_icon":0},{"id":"2590580986","title":"Jiangsu Hengrui Medicine Co. Ltd. Announces Date for 2025 Second Extraordinary Shareholders' Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2590580986","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590580986?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:46","pubTimestamp":1765374373,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine Co. Ltd. will hold its 2025 Second Extraordinary Shareholders' Meeting on December 31, 2025, in Shanghai. During the meeting, shareholders will consider and vote on a special resolution to approve proposed amendments to the articles of association of the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL8Z56Cp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828474.EUR","LU2097828805.USD","LU1655091616.SGD","LU1255011170.USD","LU1328615791.USD","LU1064131003.USD","LU2488822045.USD","LU2148510915.USD","LU2097828557.USD","LU1781817850.SGD","LU0405327148.USD","LU1146622755.USD","LU0405327494.USD","600276","BK0196","LU2580892862.HKD","LU1997245094.SGD","LU2289578879.USD","BK0239","BK0060","LU1969619763.USD","LU2097828714.EUR","LU1064130708.USD","LU1580142542.USD","LU1997245177.USD","BK0188","LU2097828631.EUR","BK0183","LU1820825898.SGD","LU1997244956.HKD","LU2328871848.SGD","LU2580892789.USD","BK0012","LU2495084118.USD","BK0028"],"gpt_icon":0},{"id":"1167236021","title":"Hengrui Pharma Facilitates Chinese Medical Excellence at Italian Digestive Surgery Conference for Second Consecutive Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1167236021","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167236021?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:02","pubTimestamp":1765281765,"startTime":"0","endTime":"0","summary":"The 36th Annual Meeting of the Italian Digestive Surgery Society concluded successfully in Rome from November 27 to 28. As one of Europe's largest academic gatherings in digestive surgery, this...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1997245094.SGD","LU2289578879.USD","BK0196","LU2580892862.HKD","LU0405327148.USD","LU1064130708.USD","LU2543165471.USD","BK0028","LU1580142542.USD","LU1820825898.SGD","LU1023057109.AUD","LU2495084118.USD","LU1146622755.USD","LU2097828805.USD","LU1328615791.USD","LU1655091616.SGD","LU1997245177.USD","LU1064131003.USD","LU2097828631.EUR","BK0060","LU1969619763.USD","LU0359202008.SGD","LU0405327494.USD","LU0359201885.HKD","BK0183","BK0012","600276","LU0359201612.USD","BK0188","LU1781817850.SGD","01276","LU2488822045.USD","LU2097828714.EUR","LU2328871848.SGD","BK0239","LU1997244956.HKD","LU2097828474.EUR","LU1255011170.USD","BK1191","159891","LU2097828557.USD","LU2148510915.USD","LU2580892789.USD"],"gpt_icon":0},{"id":"1128895116","title":"HENGRUI PHARMA (01276) Has Multiple Drugs Included in National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=1128895116","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128895116?lang=en_us&edition=fundamental","pubTime":"2025-12-07 18:44","pubTimestamp":1765104257,"startTime":"0","endTime":"0","summary":"HENGRUI PHARMA (01276) announced that several of its products have been included in the National Reimbursement Drug List (NRDL) for 2025, as per the notice jointly issued by the National Healthcare...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828805.USD","LU2488822045.USD","LU2543165471.USD","LU1997244956.HKD","LU1580142542.USD","LU2495084118.USD","LU2580892789.USD","01276","LU1969619763.USD","LU0359202008.SGD","600276","BK0188","BK0239","BK0028","BK0012","LU2148510915.USD","LU0405327148.USD","LU1255011170.USD","LU1655091616.SGD","BK0060","BK0183","LU1820825898.SGD","LU0359201612.USD","LU1997245177.USD","BK0196","LU0359201885.HKD","LU1064130708.USD","LU2097828557.USD","LU1997245094.SGD","LU2097828631.EUR","LU1781817850.SGD","LU2328871848.SGD","LU2580892862.HKD","LU1146622755.USD","LU2097828474.EUR","LU2097828714.EUR","BK1191","LU1328615791.USD","LU1064131003.USD","LU2289578879.USD","LU0405327494.USD","LU1023057109.AUD"],"gpt_icon":0},{"id":"2589087102","title":"Jiangsu Hengrui Medicine Drugs Added to China’s National Reimbursement Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589087102","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589087102?lang=en_us&edition=fundamental","pubTime":"2025-12-07 18:32","pubTimestamp":1765103562,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced that several of its drugs have been included in the National Reimbursement Drug List  in China. The updated NRDL will be officially implemented from January 1, 2026, facilitating the sales of the company's products. The company noted that the inclusion may impact its business performance, though the extent cannot be estimated at this time. Payment standards and reimbursement details will be determined by official announcements from the National Healthcare Security Administration and relevant authorities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Se","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL3SC306:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828474.EUR","LU1997245094.SGD","BK0188","BK0196","LU2580892789.USD","LU2289578879.USD","LU0405327494.USD","LU1997244956.HKD","LU1255011170.USD","LU2495084118.USD","600276","LU2328871848.SGD","LU1655091616.SGD","LU1997245177.USD","LU1146622755.USD","BK0012","LU0405327148.USD","LU1328615791.USD","LU2097828631.EUR","LU1064131003.USD","NHC","BK4185","BK0060","LU2097828805.USD","LU2097828557.USD","LU2148510915.USD","LU1064130708.USD","BK0028","LU1820825898.SGD","LU1969619763.USD","BK0183","LU2097828714.EUR","LU2580892862.HKD","LU2488822045.USD","LU1580142542.USD","BK0239","LU1781817850.SGD"],"gpt_icon":0},{"id":"2588288972","title":"Chinese Biotech Ming Yu Well Positioned For A Strong Hong Kong IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2588288972","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588288972?lang=en_us&edition=fundamental","pubTime":"2025-12-04 20:05","pubTimestamp":1764849900,"startTime":"0","endTime":"0","summary":"Led by a former research chief at drugs giant Hengrui, the Chinese biotech can boast solid credentials and big-name backers as it positions for a Hong Kong IPO. A biotech founded by a former executive ofHengrui Pharma will be looking to bask in a halo effect as it files for a stock market listing.Hengrui shares were warmly received on the Hong Kong Stock Exchange earlier this year, and nowMing Yu Pharmaceutical Ltd.is bidding for a place in the equity arena alongside the drugs giant, with Morgan Stanley, BofA Securities and CITIC Securities acting as jointIPOsponsors.Ming Yu was set up in 2018 by Cao Guoqing, a biochemist with an international profile in cutting-edge drug research. Cao gained a U.S. doctorate and worked in a senior role for Eli Lilly before joining Hengrui, where he supervised work on antibody-based therapies and small molecule drugs as vice president of biologics research.Another Ming Yu drug under development, MH004, blocks Janos kinase  enzymes linked to inflammatio","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/04/image_0.png?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/04/image_0.png?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/Opinion/25/12/49204817/chinese-biotech-ming-yu-well-positioned-for-a-strong-hong-kong-ipo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/Opinion/25/12/49204817/chinese-biotech-ming-yu-well-positioned-for-a-strong-hong-kong-ipo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU1064130708.USD","LU1997245177.USD","LU0405327148.USD","LU1255011170.USD","BK0028","LU1781817850.SGD","LU2289578879.USD","LU2097828714.EUR","LU1997244956.HKD","LU0405327494.USD","LU2097828474.EUR","BK0239","LU2097828805.USD","BK0183","BK0188","600276","LU1580142542.USD","LU2328871848.SGD","LU2495084118.USD","BK0012","LU1328615791.USD","BK0060","LU2580892789.USD","LU2097828557.USD","LU1146622755.USD","LU1655091616.SGD","LU2148510915.USD","LU2488822045.USD","LU1997245094.SGD","LU2580892862.HKD","LU1969619763.USD","BK0196","LU1064131003.USD","LU2097828631.EUR","LU1820825898.SGD"],"gpt_icon":0},{"id":"2588901018","title":"Jiangsu Hengrui Medicine Appoints Zhu Guoxin as Senior Vice President at Board Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2588901018","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588901018?lang=en_us&edition=fundamental","pubTime":"2025-12-03 18:57","pubTimestamp":1764759446,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine Co. Ltd. convened the twentieth meeting of the ninth session of its Board of Directors via teleconference on December 3, 2025. All 11 directors were present at the meeting, which was held in accordance with the Company Law of the People's Republic of China and the company's Articles of Association. During the meeting, the Board carefully considered and approved the proposal on the nomination and appointment of Mr. Zhu Guoxin as Senior Vice President. Mr. Zhu's term will commence immediately following the approval and will continue until the expiration of the current Board's term.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDLc89py:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0188","LU1328615791.USD","LU0405327148.USD","LU2495084118.USD","LU2488822045.USD","LU1146622755.USD","LU1969619763.USD","LU1997245094.SGD","LU2580892789.USD","LU2097828714.EUR","LU1997244956.HKD","BK0239","LU1781817850.SGD","LU1064130708.USD","LU2148510915.USD","LU1064131003.USD","BK0196","LU2580892862.HKD","LU1997245177.USD","LU1820825898.SGD","BK0183","LU2097828805.USD","LU1655091616.SGD","LU0405327494.USD","LU2097828474.EUR","LU2328871848.SGD","BK0060","LU1255011170.USD","BK0012","LU2097828557.USD","LU2097828631.EUR","LU2289578879.USD","600276","LU1580142542.USD"],"gpt_icon":0},{"id":"1160859833","title":"FTSE China 50 Index Rebalance: Adds CHINAHONGQIAO (01378), CATL (03750), HENGRUI PHARMA (01276), Removes CSC (06066) and Others","url":"https://stock-news.laohu8.com/highlight/detail?id=1160859833","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160859833?lang=en_us&edition=fundamental","pubTime":"2025-12-03 18:54","pubTimestamp":1764759259,"startTime":"0","endTime":"0","summary":"On December 3, FTSE Russell announced adjustments to the FTSE China 50 Index, FTSE China A50 Index, FTSE China A150 Index, FTSE China A200 Index, and FTSE China A400 Index. The changes will take...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0244354667.USD","LU0880133367.SGD","LU1997245094.SGD","LU0370786039.SGD","LU3063872942.SGD","SGXZ49509284.SGD","LU0516422366.SGD","LU1868838027.USD","LU0192582467.USD","LU2476274720.SGD","LU0572939691.SGD","LU0502904849.HKD","BK0028","BK4141","LU0543330483.HKD","LU1051768304.USD","BK0012","LU2580892862.HKD","LU0140636845.USD","BK4588","LU1831875114.USD","LU0269904917.USD","LU2298322129.HKD","SG9999002463.SGD","LU0072462343.USD","LU2097828805.USD","IE0032431581.USD","LU1064130708.USD","LU2153592121.USD","LU0181495838.USD","BK0183","LU0320764755.SGD","LU1242518931.SGD","LU0469268626.HKD","LU0128522157.USD","LU0821914370.USD","LU0463099449.HKD","LU1934453819.USD","BK1147","LU0702159699.USD","LU2097828474.EUR","LU2238339852.HKD","LU1769817179.HKD","BK1594","LU0326948709.USD","LU2097828557.USD","LU0214875030.USD","LU0312595415.SGD","LU0314109678.HKD","LU0823426308.USD","300750","LU0039217434.USD","LU1868837565.USD","LU0254981946.USD","LU0823426480.USD","01276","LU1152091168.USD","03750","LU0143863784.USD","IE00B8L5B284.USD","LU0516422440.USD","LU1781817850.SGD","LU1861214812.USD","SG9999001846.SGD","LU0054450605.USD","LU2488822045.USD","BK0239","IE00BZ199S13.USD","LU0149534421.HKD","BK4585","LU1770034418.SGD","LU0828238088.HKD","LU2242644610.SGD","LU1188198961.HKD","LU0651947912.USD","BK1175","LU1979443071.USD","LU1961090484.USD","LU2506952253.HKD","LU0823414478.USD","IE00BD6J9T35.USD","LU2506951792.HKD","LU0823437842.USD","LU1813983027.USD","IE00B3M56506.USD","LU2097828714.EUR","LU0327786744.USD","LU0049853897.USD","LU1719994722.HKD","LU0449515922.USD","LU0106259558.USD","LU0047713382.USD","LU1807302812.USD","LU2348774022.SGD","LU0359201885.HKD","LU2294711713.HKD","BK0188","600276","LU0611395673.USD","LU1794554557.SGD","LU0572940350.SGD","LU1051769294.HKD","IE00B543WZ88.USD","LU0106959298.USD","LU0593848301.USD","LU1102505762.USD","SG9999000327.SGD","SG9999003461.SGD","LU0359202008.SGD","LU0164872284.USD","LU0231483743.USD","LU2153591404.USD","SG9999001689.USD","LU0516423174.USD","LU0455707207.USD","LU1880383366.USD","LU0143863198.USD","LU0264606111.USD","LU0107464264.USD","LU2476274308.USD","LU1808992512.USD","LU0516422952.EUR","LU1102505929.USD","BK4526","LU1064131003.USD","SG9999000459.SGD","BK1116","SGXZ81163826.USD","LU1166156734.SGD","LU1580142542.USD","LU0737861699.HKD","LU1328277881.USD","LU0607220059.USD","LU0348805143.USD","LU1008478684.HKD","LU0287142896.SGD","LU1023057109.AUD","LU0405327494.USD","LU2289578879.USD","LU1861219969.SGD","LU0871576103.HKD","BK0060","LU2778985437.USD","LU2360107325.USD","LU1960683339.HKD","BK4519","LU0328353924.USD","LU2357125470.USD","LU0307460666.USD","LU0516423091.SGD","LU1255011170.USD","LU0594300179.USD","LU0188438112.USD","LU1224709979.USD","LU1969619763.USD","LU0651946864.USD","LU0828237940.HKD","LU0302445910.USD","LU2399975544.HKD","LU0724618433.USD","LU0173614495.USD","LU0531970944.HKD","LU1880383440.USD","LU2328871848.SGD","LU2506952337.HKD","LU1152091754.HKD","LU0588546209.SGD","LU0051755006.USD","IE0003795394.USD","SG9999002828.SGD","LU0672654166.SGD","BK1592","EVS.SI","LU2148510915.USD","LU0029875118.USD","JKS","LU0505663152.USD","LU2152927971.USD","LU0124384867.USD","LU2543165471.USD","LU1820825898.SGD","LU0359201612.USD","LU2424517915.HKD","LU0210526637.USD","IE00BPRC5H50.USD","LU1303224171.USD","01378","LU0164865239.USD","LU1655091616.SGD","LU0048388663.USD","LU2249611893.SGD","LU0449509016.USD","LU2580892789.USD","LU2495084118.USD","LU1048588211.SGD","LU2348773727.SGD","LU2449936058.SGD","LU2298064838.USD","BK0196","LU0132412106.USD","LU2275660780.HKD","LU0405327148.USD","LU1251922891.USD","LU1939255532.USD","BK1500","LU1978683503.SGD","LU1769817096.USD","LU2477742899.HKD","LU1242518857.USD","BK0224","LU1146622755.USD","BK1610","06066","IE0003851619.USD","LU0509642566.USD","SG9999001903.USD","LU0228659784.USD","LU0650527681.SGD","LU1515016050.SGD","BK1191","LU1721428347.USD","LU0011963245.USD","LU0594300419.USD","LU0979878070.USD","LU1039395188.USD","LU1048596156.SGD","LU2097828631.EUR","IE00B8HQ1Z84.USD","LU1993786604.SGD","SG9999001093.SGD","LU0828237510.HKD","LU0531971595.HKD","LU0456827905.SGD","LU0048580855.USD","LU0572944931.SGD","LU0106252389.USD","LU0823414551.USD","LU1720050803.USD","BK1564","LU0605514214.HKD","LU1997244956.HKD","LU1997245177.USD","IE00B5MMRT66.SGD","LU0259732245.USD","LU0326950275.SGD","LU2039709279.SGD","LU0067412154.USD","LU2506952410.USD","LU1328615791.USD"],"gpt_icon":1},{"id":"1184876987","title":"GIC Private Limited Increases Stake in Hengrui Pharma (01276) by 422,400 Shares at HK$74.96 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1184876987","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184876987?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:34","pubTimestamp":1764592452,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on November 27, GIC Private Limited acquired an additional 422,400 shares of Hengrui Pharma (01276) at HK$74.955 per share, totaling...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828631.EUR","LU1064131003.USD","01276","LU2097828557.USD","LU2488822045.USD","LU2097828474.EUR","LU2580892789.USD","LU1997245094.SGD","LU2097828805.USD","LU1997245177.USD","LU2580892862.HKD","LU1064130708.USD","LU2543165471.USD","BK1191","LU2148510915.USD","LU2289578879.USD","LU1023057109.AUD","LU2328871848.SGD","BK0196","BK0239","BK0028","LU0359201885.HKD","LU1580142542.USD","LU0405327148.USD","LU1997244956.HKD","BK0060","GIC","LU0359201612.USD","LU1655091616.SGD","LU1781817850.SGD","LU1969619763.USD","LU1820825898.SGD","LU2097828714.EUR","LU0359202008.SGD","600276","LU1328615791.USD","LU1146622755.USD","BK0183","BK0188","LU2495084118.USD","LU1255011170.USD","BK0012","BK4104","LU0405327494.USD"],"gpt_icon":0},{"id":"2587736486","title":"CSPC Feels The Pain From Sweeping Cuts In Drug Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=2587736486","media":"Benzinga_recent_news","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587736486?lang=en_us&edition=fundamental","pubTime":"2025-11-28 23:44","pubTimestamp":1764344640,"startTime":"0","endTime":"0","summary":"The pharmaceutical giant is paying the price for its aggressively low bids in China's centralized drug tenders, as it shifts its focus from traditional to novel drugs. In business as in medicine, a remedy can take time to kick in.This is the challenge for Chinese drug giantCSPC Pharmaceutical Group Ltd., which is trying to transform itself from being a supplier of established medications to a creator of innovative therapies.The transition is proving painful. Despite heavy investment in R&D, the benefits from the strategy shift have yet to translate into a rising bottom line, while the company's legacy business remains under pressure.A volume-based procurement process in 2024 for cities and provinces including Beijing, Tianjin and Hebei had already resulted in a 23% price drop for the drug. In the national","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/28/c57084f64987f461768327a3a4d1555a.png?optimize=medium&dpr=2&auto=webp&width=120","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/28/c57084f64987f461768327a3a4d1555a.png?optimize=medium&dpr=2&auto=webp&width=120"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/Opinion/25/11/49116508/cspc-feels-the-pain-from-sweeping-cuts-in-drug-prices","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/Opinion/25/11/49116508/cspc-feels-the-pain-from-sweeping-cuts-in-drug-prices","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK0188","LU2580892789.USD","BK0183","LU2328871848.SGD","BK0196","LU2097828631.EUR","LU1146622755.USD","LU2488822045.USD","LU0405327148.USD","BK0012","LU1781817850.SGD","LU1997245094.SGD","LU2097828474.EUR","LU2097828714.EUR","LU2097828805.USD","BK0060","LU1655091616.SGD","LU1820825898.SGD","LU1580142542.USD","LU1997245177.USD","LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","LU2580892862.HKD","600276","LU1255011170.USD","BK0028","LU0405327494.USD","BK0239","LU1997244956.HKD","LU2097828557.USD","LU2495084118.USD","LU1969619763.USD","LU1328615791.USD","LU2289578879.USD"],"gpt_icon":0},{"id":"1191348629","title":"Morgan Stanley Increases Stake in Hengrui Pharma by 1.77 Million Shares at Average Price of HK$69.65","url":"https://stock-news.laohu8.com/highlight/detail?id=1191348629","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191348629?lang=en_us&edition=fundamental","pubTime":"2025-11-28 07:30","pubTimestamp":1764286246,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on November 24, Morgan Stanley increased its stake in Hengrui Pharma (01276) by approximately 1.77 million shares at an average price...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023251221.USD","LU0006306889.USD","LU0158827948.USD","LU0359201885.HKD","LU1720051108.HKD","LU1820825898.SGD","LU2097828805.USD","LU1548497426.USD","LU0528227936.USD","LU2488822045.USD","MS","LU0320765646.SGD","LU0359202008.SGD","LU2089283258.USD","LU0158827781.USD","LU2580892862.HKD","LU1655091616.SGD","LU1255011170.USD","LU1969619763.USD","LU1732799900.SGD","01276","LU1244550577.SGD","LU1997245177.USD","LU2148510915.USD","LU2133065610.SGD","BK4516","IE00BKVL7J92.USD","LU1997245094.SGD","LU2111349929.HKD","LU0106261372.USD","BK0028","BK0012","LU0314104364.USD","LU2580892789.USD","LU1146622755.USD","LU0106831901.USD","LU1580142542.USD","LU0225283273.USD","LU1720051017.SGD","LU2097828631.EUR","LU1064131003.USD","LU0912757837.SGD","BK4585","LU1791710400.SGD","LU2097828557.USD","IE00BZ1G4Q59.USD","LU0234570918.USD","LU1023057109.AUD","LU0359201612.USD","LU0795875086.SGD","BK0060","BK0188","LU0405327494.USD","LU2089284900.SGD","BK4127","LU2347655156.SGD","BK1191","LU0882574139.USD","LU1074936037.SGD","BK4588","BK4534","LU1363072403.SGD","LU2028103732.USD","LU2357305700.SGD","BK0196","LU2328871848.SGD","BK4504","LU1732800096.USD","LU0405327148.USD","LU2543165471.USD","LU1162221912.USD","LU1244550221.USD","LU1781817850.SGD","LU0971096721.USD","LU1328615791.USD","LU1989772923.USD","LU2097828474.EUR","LU1064130708.USD","BK0239","LU1244550494.USD","LU2289578879.USD","LU0557290698.USD","LU0795875169.SGD","LU0267386448.USD","LU0098860793.USD","BK0183","LU2495084118.USD","LU1997244956.HKD","BK4581","LU1989772840.SGD","LU2097828714.EUR","600276","LU1668664300.SGD","LU1791710582.SGD","LU2271345857.HKD"],"gpt_icon":0},{"id":"1136133273","title":"Wellington Management Group LLP Increases Stake in Hengrui Pharma (01276) by 1 Million Shares at HK$69.15 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=1136133273","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136133273?lang=en_us&edition=fundamental","pubTime":"2025-11-26 19:30","pubTimestamp":1764156638,"startTime":"0","endTime":"0","summary":"Latest data from the Hong Kong Stock Exchange shows that on November 24, Wellington Management Group LLP increased its stake in Hengrui Pharma (01276) by 1 million shares at HK$69.15 per share,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","LU1064130708.USD","LU1146622755.USD","LU2097828714.EUR","BK0239","600276","LU1580142542.USD","LU2097828631.EUR","LU2097828805.USD","LU0405327148.USD","LU2097828557.USD","LU1781817850.SGD","LU1997245094.SGD","LU2289578879.USD","LU0405327494.USD","BK0012","LU2580892789.USD","LU2097828474.EUR","01276","LU1655091616.SGD","LU2328871848.SGD","LU0359201885.HKD","BK1191","LU1820825898.SGD","BK0183","LU1328615791.USD","LU1023057109.AUD","LU1255011170.USD","LU2488822045.USD","LU0359202008.SGD","BK0028","LU2543165471.USD","LU2580892862.HKD","LU1969619763.USD","LU0359201612.USD","LU2148510915.USD","BK0188","LU1997245177.USD","LU1997244956.HKD","LU2495084118.USD","BK0060","LU1064131003.USD"],"gpt_icon":0},{"id":"1199951165","title":"HENGRUI PHARMA (600276.SH): HRS-8364 Tablets Approved for Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1199951165","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199951165?lang=en_us&edition=fundamental","pubTime":"2025-11-25 16:54","pubTimestamp":1764060871,"startTime":"0","endTime":"0","summary":"HENGRUI PHARMA (600276.SH) announced that it has received the \"Drug Clinical Trial Approval Notice\" for HRS-8364 tablets from the National Medical Products Administration and will soon conduct...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1781817850.SGD","LU2543165471.USD","BK1191","LU1255011170.USD","LU1655091616.SGD","BK0239","LU1820825898.SGD","LU2488822045.USD","LU1023057109.AUD","LU2289578879.USD","LU1969619763.USD","BK0012","LU2580892789.USD","LU2580892862.HKD","LU2495084118.USD","LU2097828805.USD","LU2148510915.USD","01276","LU1064131003.USD","LU2097828474.EUR","LU1997245177.USD","BK0183","600276","LU1328615791.USD","LU0405327494.USD","LU0405327148.USD","LU0359201612.USD","LU2097828557.USD","LU2097828714.EUR","LU1064130708.USD","LU2097828631.EUR","LU1146622755.USD","BK0028","BK0188","BK0060","LU2328871848.SGD","LU0359201885.HKD","LU1580142542.USD","LU1997245094.SGD","BK0196","LU1997244956.HKD","LU0359202008.SGD"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","stockEarnings":[{"period":"1week","weight":-0.0536},{"period":"1month","weight":-0.0288},{"period":"3month","weight":-0.1385},{"period":"6month","weight":0.1592},{"period":"1year","weight":0.2925},{"period":"ytd","weight":0.3119}],"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","perCapita":"16058股","boardName":"医药制造业","registeredCapital":"663719万元","compareEarnings":[{"period":"1week","weight":0.0008},{"period":"1month","weight":-0.0161},{"period":"3month","weight":0.0147},{"period":"6month","weight":0.1537},{"period":"1year","weight":0.1461},{"period":"ytd","weight":0.1565}],"survey":"　　江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是硫培非格司亭注射液、马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇胺片、碘佛醇注射液。","serverTime":1766102192303,"listedPrice":11.98,"stockholders":"397246人(较上一季度增加8.94%)","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.,600276,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票老虎国际,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票行情,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股价,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股市,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票价格,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票交易,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票购买,Jiangsu Hengrui Pharmaceuticals Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Jiangsu Hengrui Pharmaceuticals Co.,Ltd.(600276) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction